PA
SGMO

Profund Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Profund Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-64,480
Closed -$65.8K – 1095
2024
Q4 		$65.8K Buy
+64,480
New +$118K ﹤0.01% 1090
2023
Q2 		– Sell
-114,668
Closed -$202K – 1128
2023
Q1 		$202K Buy
+114,668
New +$327K 0.01% 1001

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Profund Advisors's SGMO Position: Q1 2025 in Review

Profund Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2025, closing a stake of 64,480 shares — an estimated $65.8K sold.

Profund Advisors first reported a position in SGMO in Q1 2023 and held it in 2 quarters. The position peaked at $202K in Q1 2023. 122 funds tracked by Wall St. Rank hold SGMO as of Q1 2025.

  • Profund Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2025 after selling out during the quarter.
  • Profund Advisors sold 64,480 SANGAMO THERAPEUTICS INC shares in Q1 2025, an estimated $65.8K.
  • Profund Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q1 2023 and held it in 2 quarters.
  • Profund Advisors's SANGAMO THERAPEUTICS INC position peaked at $202K in Q1 2023.
  • 122 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2025.

Based on Profund Advisors's 13F filing for Q1 2025, filed 8 May 2025.